NEFL and frontotemporal dementia: In the ALLFTD cohorts, plasma NfL discriminated the presymptomatic from symptomatic mutation carriers, with a cutoff of 13.6 pg/ml in the original cohort and 19.8 pg/ml in the validation group.3 Data from these international cohorts demonstrate that neurodegeneration in genetic FTLD, as measured by blood NfL, has the potential to reflect disease progression and that the specific FTD gene mutation may dictate recommended cutoff thresholds.